Abstract
Commencing with the discovery and characterization of bispecific antibodies, numerous investigations have shown that such antibodies are capable of redirecting cellular cytotoxicity. Clinical trials testing diverse strategies, including those targeting CD16-expressing effector cells, have been conducted or are in progress. This manuscript reviews our clinical trials efforts with bispecific antibodies and describes our experience employing multifunctional binding proteins containing tumor-targeting antibody Fab fragments linked to bacterial superantigens, such as staphylococcal enterotoxin A.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Accepted: 14 October 1997
Rights and permissions
About this article
Cite this article
Weiner, L., Alpaugh, R. & von Mehren, M. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins. Cancer Immunol Immunother 45, 190–192 (1997). https://doi.org/10.1007/s002620050430
Issue Date:
DOI: https://doi.org/10.1007/s002620050430